Evotec Heads Into November 5 With a Confirmed Outlook, a Negative EBITDA and a New Science Chief
Published on 11/03/2026 at 13:11 | Editorial boerse-global.de
Evotec will publish full results for the third quarter and the first nine months of 2026 on November 5, with a webcast and conference call scheduled to begin at 14:00 CET. The date arrives against a backdrop of three developments that investors should keep apart: a reaffirmed full-year forecast, a still-negative adjusted operating result, and a leadership change at the top of the science function.
What the preliminary figures already show
The starting point is the preliminary release of October 13. For the first nine months of 2026, Evotec reported unaudited group revenue of roughly EUR 465.0 million and an adjusted group EBITDA of about EUR -42.8 million. Alongside those numbers, the company confirmed its guidance for the full year.
Two signals therefore sit side by side. Management stood by its annual outlook even as the adjusted operating line stayed in the red. A reaffirmed forecast is not the same thing as a return to profit — it means the company still regards its existing guidance as the relevant yardstick. The loss figure remains central to any reading of the business, and so does its status: these are preliminary, unaudited figures, not the completed report. That distinction is precisely what the upcoming release is meant to resolve.
RBC cuts its target, but the model is the reason
Ahead of the final numbers, RBC Capital Markets lowered its price target on Friday from EUR 10 to EUR 5, citing an adjustment to its valuation model, according to dpa-AFX. The broker also flagged the investment as speculative.
Should investors sell immediately? Or is it worth buying Evotec?
That move is a re-rating by the research house, not a change to the company's own guidance. The two statements need to be held separately: a confirmed outlook does not prevent analysts from assigning a lower value to the business derived from it. The preliminary figures describe operating performance; the price target expresses a valuation. No additional operational deterioration can be inferred from the cut on its own.
A new chief scientific officer, effective since Sunday
Separately, Evotec announced on October 15 that Joanna Holbrook would become Chief Scientific Officer and a member of the management board, a appointment effective since Sunday. Science leadership now sits directly inside the executive team.
The personnel decision and the financial report operate on different levels — governance on one side, business performance on the other. Nothing in the appointment alone points to an improvement in the numbers. The report is the concrete checkpoint for the financial picture.
Timing matters here too. The reporting period predates Holbrook taking office, so the nine-month figures are not a scorecard for the new science chief. A fresh face at the top is an organisational step; whether the economic situation shifts with it has to be judged from the company's reported figures.
Evotec at a turning point? This analysis reveals what investors need to know now.
The share count has moved as well
On October 28, Evotec published a total of 177,948,497 voting rights, naming October 20 as the effective date of the conditional capital increase. The mandatory disclosure concerns the capital and voting base rather than operating results. It sits alongside the personnel changes but says nothing about how the business is trading.
What November 5 has to deliver
The announced financial report remains the decisive event. It will show what economic results Evotec sets against its reshaped leadership and capital structure. The reported business figures are what count — not the organisational changes taken by themselves. For investors, the key split stays the same: planning certainty on the outlook does not yet amount to operating profitability.
Ad
Evotec Stock: New Analysis - 3 November
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
